Purpose: Hypovascular nodules that exhibit hypointensity in hepatocyte-phase images of gadoxetic acid-enhanced magnetic resonance (MR) imaging are frequently encountered in clinical practice. We investigated risk factors for the development of these nodules into hypervascular hepatocellular carcinoma (HCC).
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths. [1] [2] [3] The prognosis for patients with this disease remains dismal because of its aggressive nature and frequent association with underlying cirrhosis. To improve the possibility of therapeutic intervention and patient survival, early detection of HCC is vital. [4] [5] [6] However, despite eŠorts to improve the diagnostic accuracy of noninvasive imaging methods, the sensitivity and speciˆcity of dynamic multidetector computed tomography (CT) and magnetic resonance (MR) imaging for detecting HCCs smaller than 2 cm remain unsatisfactory. 7, 8 The limitations of these modalities are mainly because of the di‹culty in detecting hypovascular and isovascular lesions that occur during the early stages of multistep hepatocarcinogenesis. 9 Gadoxetic acid is a recently developed MR contrast agent that is speciˆcally taken up by hepatocytes and provides a better lesion-liver contrast, which is not achievable with extracellular gadolinium-based agents. [10] [11] [12] Gadoxetic acid-enhanced MR imaging is known to have a higher sensitivity than dynamic CT for detecting HCC, especially le-D. Joishi et al.
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sions smaller than 2 cm in diameter. [13] [14] [15] Therefore, this technique may more readily detect early-stage lesions than CT arterial portography, 16 which was believed to have the highest sensitivity for this purpose. 9 The increased use of gadoxetic acid for routine examination may lead to the more frequent detection of hypovascular nodules that are hypointense on hepatocyte-phase (15 to 20 min after administration of gadoxetic acid) images of gadoxetic acidenhanced MR imaging. However, the management of these nodules is a contentious issue. Several recent studies have reported the detection of hypovascular nodules by gadoxetic acid-enhanced MR imaging, [17] [18] [19] [20] [21] though the occurrence of hypervascular HCC varied. For this reason, we believe that results from diŠerent groups of patients are important to identify a treatment or surveillance strategy for these small hypovascular nodules.
The purpose of the present study was to investigate the risk factors for hypovascular nodules developing into hypervascular HCC.
Methods

Patients
This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by our institutional review board. The need for written informed consent was waived because of the retrospective design of the study.
We retrospectively reviewed our institutional database and identiˆed 302 patients who underwent gadoxetic acid-enhanced MR imaging for suspected or conˆrmed HCC from February 1, 2008 
MR imaging protocol
MR imaging in this study was performed with a 1.5-(Signa ES version 11.1, Signa HD TS version 12, GE Healthcare, Waukesha, WI, USA) or 3-tesla (Discovery MR750, GE Healthcare) scanner using either an 8-(1.5T) or 32-channel (3T) body-array surface coil. First, a T 1 -weighted fast spoiled gradient echo (T 1 W-FSPGR) sequence was obtained using in-and opposed-phase imaging. Next, noncontrast images with fat-suppressed T 1 -weighted gradient echo imaging with a 3D acquisition sequence (liver acquisition with volume acceleration [LAVA]) were obtained with a parallel imaging technique (array spatial sensitivity encoding technique [ASSET]; factor＝2); scanning time was 16 to 20 s. For dynamic scans, the contrast agent (0.025 mmol/kg; 0.1 mL/kg) was administered over 4 seconds followed by a 30-mL saline ‰ush using a power injector (Sonic Shot GX, NemotoKyorindo, Tokyo, Japan). Fluoroscopic triggering was used to determine the timing of the arterialphase image. After administration of 0.025 mmol/ kg gadoxetic acid, arterial-, portal venous-(60 s after injection), and late-phase (120 to 180 s after injection) images were sequentially obtained. Between the late phase andˆnal hepatocyte phase (15 to 20 min), T 2 -weighted single-shot fast spin-echo sequence, fat-suppressed T 2 -weighted fast spin-echo sequence, and diŠusion-weighted images (DWIs) were obtained.
CT protocol
CT was performed with 64-multidetector-row scanners-LightSpeed VCT (GE Healthcare), Discovery 750 HD (GE Healthcare), or Aquilion 64 (Toshiba Medical Systems, Otawara, Japan). After acquisition of precontrast CT images, 2 mL/kg of a nonionic contrast medium was administered intravenously for 30 s using a power injector (Dual Shot Type-D, NemotoKyorindo). Arterial-phase images were obtained after a scan delay of 40 s, portal venous-phase images after 80 s, and equilibrium-phase images after 180 s. The slice thickness of precontrast images was 5.0 mm, and that of postcontrast images was 1.25 mm.
Nodules
We included nodules that demonstrated (1) round or oval shape and hypointense appearance on hepatocyte-phase images in both the axial and coronal planes; (2) no hypervascularity on arterialphase images obtained using dynamic CT or gadoxetic acid-enhanced MR imaging; and (3) no distinct high signal intensity on T 2 -weighted images (T 2 WIs) that suggested hemangioma and cyst and nodules that were (4) detected before interventional treatment.
In the case of follow-up assessment, we included those monitored longer than 6 months.
Assessment of nodule hypervascularization
We assessed hypervascularization using gadoxetic acid-enhanced MR imaging or dynamic CT. Hypervascular HCC was deˆned when a nodule showed hyperintensity in arterial-phase images and hypointensity in hepatocyte-phase images of gadoxetic acid-enhanced MR imaging or in portal venous-or equilibrium-phase images of dynamic CT. A lesion that was isointense in arterial-phase images and hypointense in precontrast images was also deemed hypervascular HCC.
Image interpretation
Together, 2 radiologists (D.J. and A.U., with 8 and 11 years' experience in hepatobiliary imaging) evaluated the gadoxetic acid-enhanced MR imaging and dynamic CT using a picture archiving and communication systems (PACS). Any disagreement between the 2 readers was solved in conference with a third radiologist (A.T., 30 years' experience).
Nodule size was evaluated on axial-plane hepatocyte-phase images. The major and minor axes were measured on the monitor. Measurements were repeated 3 times, and the median size was recorded. Nodules were evaluated for the presence of fat and signal changes on T 1 -weighted images (T 1 WIs), T 2 WIs, and DWIs. The presence of fat was considered positive if the signal intensity of the nodules was decreased on opposed-phase T 1 WIs, which suggests the existence of an intracellular lipid component. In T 2 WIs and DWIs, the signal intensity of the nodule was visually classiˆed as high if it exceeded that of the liver parenchyma. On T 1 WIs, the nodule intensity was categorized as low if it was lower than that of the background liver on the precontrast LAVA images.
For patients who underwent gadoxetic acid-enhanced MR imaging 6 months or more after initial assessment, the follow-up interval and follow-up period (total follow-up time) were ascertained.
Statistical analysis
We performed statistical analysis using IBM SPSS statistics version 19.0.0 (IBM Co., Armonk, NY, USA). We used Mann-Whitney U test to compare 2 continuous values, Kruskal-Wallis one-way analysis of variance to compare 3 continuous values, and Fisher's exact test to compare proportions. Multivariate analysis of nodule imagingˆnd-ings was performed using logistic regression analysis. Kaplan-Meier time-to-event curves were used to estimate the cumulative rate of hypervascularization and were compared using the log-rank test. A 2-sided P valueº0.05 was considered signiˆcant in all analyses.
Results
Detected nodules
In 82 of the 302 patients, 178 hypovascular nodules were detected on gadoxetic acid-enhanced MR imaging. The mean number of nodules per patient was 2.2±1.9, ranging from one to 11. Eighty-one nodules in 48 patients were examined by gadoxetic acid-enhanced MR imaging only once, and 37 nodules in 12 patients were examined at least twice with a follow-up time of less than 6 months. The remaining 32 patients with 60 nodules underwent gadoxetic acid-enhanced MR imaging twice or more and were followed up after 6 months (Fig. 1) .
Ten patients had at least one nodule that was followed up and one that was examined only once.
Followed-up nodules
The median follow-up interval for the 60 nodules followed up longer than 6 months was 188 days (range, 76 to 823 days), and the median follow-up period was 492 days (range, 199 to 1002 days). The mean initial size of the nodules was 7.8±3.1 mm (range, 4 to 17 mm); 47 were smaller than 10 mm (47/60, 78z) and 58 were smaller than 15 mm (58/60, 97z). The mean number of nodules per patient was 1.9±1.3 (range, one to 5). No reduction in lesion size was found during the follow-up period. Thirty-one nodules increased in size-eight progressed to hypervascular HCC (hypervascularized nodules), and 23 remained hypovascular (grown nodules). Twenty-nine nodules remained stable in size (stable nodules) during the follow-up No signiˆcant diŠerences in age, sex, etiology of liver disease, Child-Pugh classiˆcation, tumor markers, presence of other hypervascular HCC, past history of intervention, follow-up interval, or follow-up period were found among patients with only stable nodules, grown nodules, or a combination of grown and stable nodules or with hypervascularized nodules. The presence of fat was most frequently seen in the hypervascularized nodules (Fig. 2) , as determined by univariate and multivariate analyses (Pº0.01 for both). No statistically signiˆcant diŠerences in initial nodule size, nodule signal intensity, follow-up interval, or follow-up period were observed among the stable, grown, or hypervascularized nodules (Table 1) .
Cumulative hypervascularization rate
The cumulative hypervascularization rates for the followed-up nodules were 5.1z±2.9z at one year, 13.1z±5.2z at 2 years, and 37.6z±15.9z at 3 years. Here, we considered 1002 days as 3 years in calculating the 3-year cumulative rate. Comparative analysis of nodules with and without fat showed that hypervascularization occurred earlier in those with fat (P＝0.012, Fig. 3 ). The curves of nodules larger than 10 mm and those smaller than or equal to 10 mm did not diŠer signiˆcantly.
Discussion
Gadoxetic acid-enhanced MR imaging can enable dynamic contrast and liver-speciˆc imaging. 22 A higher lesion-to-liver contrast in the hepatocyte phase may improve the sensitivity of the detection of hepatocellular lesions, [14] [15] [16] 23 especially early HCC. 24 In our study, we observed hypovascular nodules that were hypointense in the hepatocytephase images in 27.2z (82/302) of the patients who underwent gadoxetic acid-enhanced MR imaging for suspected or conˆrmed HCC.
Recent studies have shown that OATP8 is the most probable uptake transporter 25, 26 and that its expression gradually decreases during multistep hepatocarcinogenesis. 27 However, the question remains whether all hypovascular nodules detected by gadoxetic acid-enhanced MR imaging are premalignant lesions, such as high grade dysplastic nodule (HGDN) and early HCC. Because nearly half the followed-up nodules were stable in size, it cannot be assumed that all detected nodules were premalignant lesions.
To determine the timing of treatment for HCCs, it is important to ascertain lesion hypervascularity. 28 Several recent studies have reported the hypervascularization of hypovascular nodules detected on gadoxetic acid-enhanced MR imaging. [17] [18] [19] Table 2 summarizes those study results and ours. One risk factor for hypervascularization is nodule size. The results of these studies showed that nodules larger than 10 mm were at a higher risk for hypervascularization. We did notˆnd initial size of nodules to be a predictor for hypervascularization, possibly because 78z of the followed-up nodules were smaller than 10 mm and the number of the nodules was relatively small.
Another risk factor for nodule hypervascularization is the presence of fat, aˆnding of our study as well as Motosugi's. 17 Because fatty changes in nodules are a characteristic histopathological feature of HGDN and early HCC 29, 30 and a gradual decrease in OATP8 expression has been shown during multistep hepatocarcinogenesis, 27 it is reasonable to consider most hypovascular nodules with fat detected by gadoxetic acid-enhanced MR imaging to be HGDN or early HCC.
In Fig. 3, 3 nodules without fat became hyper- Our study has several limitations. First, we obtained pathologic conˆrmation in only a few cases. However, radiologicalˆndings obtained using gadoxetic acid-enhanced MR imaging are probably adequately informative for routine clinical use. Second, the follow-up interval was notˆxed because of the retrospective study design. Third, because there were many small lesions, some measurement errors associated with nodular size may have occurred; however, we carefully repeated the measurements and magniˆed the images on the PACS monitor to minimize errors. Lastly, we did not include hyperintense nodules in the hepatocyte phase.
In conclusion, the presence of intralesional fat was found to be a risk factor for hypervascularization of hypovascular nodules that exhibited hypointensity in the hepatocyte-phase images of gadoxetic acid-enhanced MR imaging.
